Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Peijia Medical Ltd. ( (HK:9996) ) has issued an announcement.
Peijia Medical reported unaudited 2025 revenue of approximately RMB700 million to RMB720 million, up about 13.7% to 17% from 2024, driven by strong growth across all three neurointerventional product lines and rising penetration in China’s TAVR market. The company highlighted robust demand for its DCwire micro guidewire, Syphonet stent retriever, Tethy AS aspiration catheter and YonFlow flow diverting stent, as well as stable balloon dilatation catheter revenue despite price cuts under volume-based procurement, thanks to higher sales volumes. In structural heart, Peijia’s commercial TAVR portfolio expanded into around 130 additional hospitals, reaching more than 780 hospitals and achieving about 3,900 implantations in 2025, a 14.4% year-on-year increase that outpaced overall market growth. The recent regulatory approval of the TaurusTrio Transcatheter Aortic Valve System for aortic regurgitation positions the company to begin broad commercialization in this segment in China, reinforcing its competitive position in the structural heart market while investors await the audited full-year results expected in March 2026.
The most recent analyst rating on (HK:9996) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
More about Peijia Medical Ltd.
Peijia Medical Limited is a Hong Kong–listed medical device company focused on neurointerventional products and structural heart therapies, particularly transcatheter aortic valve replacement (TAVR) systems. Its portfolio includes vascular access, hemorrhagic and ischemic neurointerventional devices, as well as several TAVR systems for treating aortic stenosis and aortic regurgitation in mainland China, Hong Kong and Taiwan, with a strategy centered on expanding hospital coverage and market share in these high-growth cardiovascular segments.
Average Trading Volume: 1,182,448
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.33B
See more data about 9996 stock on TipRanks’ Stock Analysis page.